Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

focafoca99 May. 21 at 10:55 PM

$ABBV disclosed new ASCO 2026 oncology data spanning solid tumors and blood cancers. https://www.rapidticker.com/news/abbv-abbvie-announces-new-data-at-4271c6

0 · Reply

Fosco_ May. 21 at 9:12 PM

$IMMX Some ASCO data is out. This morning layout perfectly anticipated tonight's ASCO abstracts. Regeneron’s Linvoseltamab ($REGN LINKER-AL2) shows solid response but highlights persistent continuous-dosing toxicity risks. AbbVie’s Ententamig ($ABBV) faces standard bispecific multi-dose fatigue. AstraZeneca/Gracell's dual CAR-T (AZD0120) requires heavy logistics/hospitalization constraints. Meanwhile, Immix’s NXC steals the show. An unparalleled 95% Complete Response rate with zero relapses locks in NXC-201 as a true one-and-done outpatient functional cure

1 · Reply

focafoca99 May. 21 at 8:53 PM

$ABBV rallies on positive CHMP opinion for Boey in Europe. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-positive-chmp-23cd11

0 · Reply

Blockwave1 May. 21 at 8:35 PM

Just THIS WEEK I gave YOU ALL over 2,799% in GAINS for COMPLETELY FREE..(STOCKSWITS)🔥 I GAVE YOU $IBM 22 MAY 26 $240 CALL FOR 1,171% 🥰 I GAVE YOU $HD 22 MAY 26 $415 CALL FOR 400% 🥰 I GAVE YOU $IBM 29 MAY 26 $245 CALL FOR 400% 🥰 I GAVE YOU $AAPL 22 MAY 26 $300 CALL FOR 263% 🥰 I GAVE YOU $COST 22 MAY 26 $1,120 CALL FOR 203% 🥰 I GAVE YOU $COST 22 MAY 26 $1,110 CALL FOR 201% 🥰 I GAVE YOU $ABBV 22 MAY 26 $222.5 CALL FOR 156% 🥰 Turn on post notifications on STOCKWITS🔥 Feel free to join the telegram channel🤙

0 · Reply

Blockwave1 May. 21 at 8:21 PM

$ABBV 🔥 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.59 🔥 156% GAINER! 🔥 To the moon🤙🚀

0 · Reply

luckyfreedom May. 21 at 6:58 PM

$COSM I am still here - just waiting for next the base. I got stopped out on my initial entry. By the way - This is not my priority investment, my time is valuable. Someone couldn’t pay me enough to post here all day long like you Jim. Other stocks I took positions on this morning: $MP $ABBV $HOOD $ANET

0 · Reply

nlrmandate May. 21 at 6:27 PM

$VKTX I've always favored $ABBV over $NVO as a buyer of Viking. However, with today's Retatrutide trial results, I actually think a BO by NVO has become MORE likely for Viking. With NVO's recent performance, it seems fairly clear that the market views NVO as yesterday's news. It can't buy Reta because LLY won't sell and because Reta isn't very tolerable as a general weight loss drug anyway (as opposed to perhaps a niche player for morbid obesity/bodybuilding). BUT, what it can do is buy the company with THE ONLY REMAINING clinical weight loss asset with the chops to challenge BOTH Terz and Reta....and that would be Viking. I still personally hope it's ABBV that buys Viking, but they need to make a move before NVO wises up and beats them to the punch! And don't think NVO can't afford Viking; from where I sit, they can't afford NOT to BO Viking! Long and insanely

5 · Reply

mebotta10 May. 21 at 5:34 PM

$HCWB $ABBV is cooked!

0 · Reply

55X_ROI_Q1_2026 May. 20 at 8:13 PM

$SLS Always nice to see a new 52 week / 5 year HIGH while waiting for Phase 3 Trial Results. $ABBV $BMY $RHHBY Know GPs is preventing relapse and Extending survival, doing what its done in ALL Previous Trials and is the only reason we are waiting for Near Miraculous Survival Data - they Own the BAT / Aza +VEN - Aza VEN Recently FAILED 3 Large Phase 3 trials conducted by $ABBV - Including 2 for AML Remission Maintenance.

0 · Reply

BillionerOfKing May. 20 at 5:40 PM

$ABBV Current Stock Price: $212.99 Contracts to trade: $212.5 ABBV May 22 2026 Call Entry: $1.99 Exit: $3.56 ROI: 79% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

2026-05-21T20:19:37.000Z - 3 hours ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

May 21, 2026, 4:10 PM EDT - 3 hours ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

2026-05-15T12:51:42.000Z - 6 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-14T20:15:24.000Z - 7 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

2026-05-14T11:07:12.000Z - 7 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

May 13, 2026, 2:20 PM EDT - 8 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 9, 2026, 10:08 AM EDT - 12 days ago

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

May 8, 2026, 10:00 AM EDT - 13 days ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 15 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

2026-05-05T12:32:52.000Z - 16 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

May 5, 2026, 8:05 AM EDT - 16 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

2026-05-04T12:13:35.000Z - 17 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

May 2, 2026, 8:45 AM EDT - 19 days ago

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AZN GSK

May 1, 2026, 3:05 PM EDT - 20 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 20 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 21 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

2026-04-30T18:00:46.000Z - 21 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T13:31:03.000Z - 21 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Apr 30, 2026, 9:00 AM EDT - 21 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

2026-04-30T10:15:57.000Z - 21 days ago

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:14:18.000Z - 21 days ago

AbbVie upgraded to Buy from Neutral at BofA

Apr 29, 2026, 2:50 PM EDT - 22 days ago

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

2026-04-29T16:41:09.000Z - 22 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:39:58.000Z - 22 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:07.000Z - 22 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

Apr 29, 2026, 9:00 AM EDT - 22 days ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 22 days ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 22 days ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 22 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 22 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 22 days ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 23 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 23 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 24 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 4 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 4 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 4 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 4 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 5 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 5 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 5 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 9, 2026, 2:00 PM EDT - 6 weeks ago

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

AMCR CVX

Apr 8, 2026, 1:38 PM EDT - 6 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 6 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 6 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 6 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 6 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 7 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 7 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 7 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 7 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 7 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

Mar 6, 2026, 8:26 AM EST - 2 months ago

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

GILD V

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Feb 24, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

focafoca99 May. 21 at 10:55 PM

$ABBV disclosed new ASCO 2026 oncology data spanning solid tumors and blood cancers. https://www.rapidticker.com/news/abbv-abbvie-announces-new-data-at-4271c6

0 · Reply

Fosco_ May. 21 at 9:12 PM

1 · Reply

focafoca99 May. 21 at 8:53 PM

$ABBV rallies on positive CHMP opinion for Boey in Europe. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-positive-chmp-23cd11

0 · Reply

Blockwave1 May. 21 at 8:35 PM

0 · Reply

Blockwave1 May. 21 at 8:21 PM

$ABBV 🔥 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.59 🔥 156% GAINER! 🔥 To the moon🤙🚀

0 · Reply

luckyfreedom May. 21 at 6:58 PM

0 · Reply

nlrmandate May. 21 at 6:27 PM

5 · Reply

mebotta10 May. 21 at 5:34 PM

$HCWB $ABBV is cooked!

0 · Reply

55X_ROI_Q1_2026 May. 20 at 8:13 PM

0 · Reply

BillionerOfKing May. 20 at 5:40 PM

0 · Reply

55X_ROI_Q1_2026 May. 20 at 5:21 PM

$SLS Must really Gobble SCHLONG being short here now, knowing the 80th EVENT IS COMING and and their Short Lies are worn thin. - 80th EVEN PR WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....

1 · Reply

OnTheBalance May. 20 at 5:00 PM

$SLS $LLY $ABBV The 80th Event is NOW Around the Corner.

0 · Reply

55X_ROI_Q1_2026 May. 20 at 4:51 PM

$SLS The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.

1 · Reply

55X_ROI_Q1_2026 May. 20 at 3:59 PM

$SLS Must really Suck A** being short here now, knowing the 80th EVENT IS COMING and WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....

0 · Reply

NEWBIGTECH May. 20 at 3:57 PM

$SLS $ABBV $PFE

0 · Reply

55X_ROI_Q1_2026 May. 20 at 3:50 PM

$SLS Phase 3 Registrational Results giving Gps the Fda green light to treat 100,000 AML Patients, currently in remission + 40/50,000 more each year - are Coming. - could be any day now. $28B TAM just for AML is worth every nickel of $40B to Big Pharma $ABBV $PFE

0 · Reply

LosersMakeMillions May. 20 at 1:21 PM

$ABBV $MRK $PFE $SLS this would be amazing 🤩 👇🏽…

0 · Reply

Mike22332233 May. 20 at 1:07 PM

$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!

1 · Reply

Mike22332233 May. 19 at 11:56 PM

1 · Reply

SellasgpsCurativeBAT11 May. 19 at 10:05 PM

$ABBV $ALPMY $NVS $SLS Trading will be halted before any Deal or Data PR! 🙏✌️❤️‍🩹

0 · Reply

TalkMarkets May. 19 at 9:49 PM

Dividend Growth Stocks: The Bedrock Of Your Retirement Portfolio $ABBV https://talkmarkets.com/article/dividend-growth-stocks-the-bedrock-of-your-retirement-portfolio-1779227312

0 · Reply

SellasgpsCurativeBAT11 May. 19 at 8:47 PM

$SLS $ABBV $NVS $ALPMY These 4 companies drugs are going to be Obsolete after GPS FDA approval: AbbVie and Genentech: Venclexta (venetoclax) Astellas Pharma: Xospata (gilteritinib) Novartis Pharmaceuticals: Rydapt (midostaurin) Bristol Myers Squibb: Onureg Combined Sellas Platform can treat entire AML from start to finish and will make $10 Billion dollar blockbusters Obsolete. ABBV and Merck will be the biggest looser of the imminent bidding war if they don’t make a move pre- GPS Regal Pivotal Registrational Phase 3 study. SLS GPS will dethrone Merck’s Keytruda as # 1 selling drug on the planet with peek sales of $35 Billion + Mark this post and frame it, Bidding war= $280.00+ 🙏✌️❤️‍🩹

0 · Reply

Market Cap	377.67B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	20.55
Forward PE	14.64
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	3,813,946
Avg Vol	6,809,734
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	78%
Beta	0.32
Analysts	Strong Sell
Price Target	$251.14